Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2013 Aug 12;12(10):10.1158/1535-7163.MCT-12-1242. doi: 10.1158/1535-7163.MCT-12-1242

Figure 2. HDAC inhibitors attenuate ATM pathway activation.

Figure 2

(A.) Cells pre-treated with vehicle or vorinostat were exposed to epirubicin for 8 hours before collection and analysis of whole cell lysate by western blot for ATM and CHK2 phoshporylation. (B.) MCF-7 cells treated were treated with increasing concentrations (48 hours) and time-points of vorinostat (1μM) (C.). ATM expression in cell lines treated with vehicle or vorinostat were determined by qRT-PCR for mRNA normalized to β-glucuronidase (h.Gus) (D.) and for total protein by western blot (E.). (*p<0.05 vs. 0.0 μM vorinostat)